Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2015

01-02-2015 | Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

What Role Does Mycobacterium avium subsp. paratuberculosis Play in Crohn’s Disease?

Author: Horacio Bach

Published in: Current Infectious Disease Reports | Issue 2/2015

Login to get access

Abstract

Crohn’s disease (CD) is a chronic, debilitating inflammatory bowel disease with no etiological agent yet identified. Studies have demonstrated that the bacterium Mycobacterium avium subsp. paratuberculosis (MAP) is present in a high percentage of CD patients. Although MAP has been isolated from human specimens, current techniques fail to show the presence of MAP in 100 % of tissues or biopsies obtained from CD patient lesions, and thus MAP cannot meet Koch’s postulate as the etiological agent of CD. In this report, the effect of genetic and immune factors as well as the presence of MAP as a potential environmental factor is analyzed.
Literature
1.
Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780–5.CrossRefPubMedCentralPubMed
2.
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–33.CrossRefPubMed
3.
Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97–108.CrossRefPubMed
4.
Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823–35.CrossRefPubMed
5.
Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996;38:365–75.CrossRefPubMedCentralPubMed
6.
Cong Y, Weaver CT, Lazenby A, Elson CO. Bacterial-Reactive T Regulatory Cells Inhibit Pathogenic Immune Responses to the Enteric Flora. J Immunol. 2002;169:6112–9.CrossRefPubMed
7.
Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–33.CrossRefPubMed
8.
Casellas F, Borruel N, Papo M, Guarner F, Antolín M, Videla S, et al. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis. 1998;4:1–5.CrossRefPubMed
9.
Greenstein RJ. Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease. Lancet Infect Dis. 2003;3:507–14.CrossRefPubMed
10.
Grant IR. Zoonotic potential of Mycobacterium avium ssp. paratuberculosis: the current position. J Appl Microbiol. 2005;98:1282–93.CrossRefPubMed
11.
Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, et al. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:607–13.CrossRefPubMed
12.
McFadden JJ, Butcher PD, Chiodini R, Hermon-Taylor J. Crohn’s disease-isolated mycobacteria are identical to Mycobacterium paratuberculosis, as determined by DNA probes that distinguish between mycobacterial species. J Clin Microbiol. 1987;25:796–801.PubMedCentralPubMed
13.
Collins MT. Update on paratuberculosis: 1. Epidemiology of Johne’s disease and the biology of Mycobacterium paratuberculosis. Ir Vet J. 2003;56:565–74.
14.
Chacon O, Bermudez LE, Barletta RG. Johne’s disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev Microbiol. 2004;58:329–63.CrossRefPubMed
15.
Godfroid J, Boelaert F, Heier A, Clavareau C, Wellemans V, Desmecht M, et al. First evidence of Johne’s disease in farmed red deer (Cervus elaphus) in Belgium. Vet Microbiol. 2000;77:283–90.CrossRefPubMed
16.
Greig A, Stevenson K, Henderson D, Perez V, Hughes V, Pavlik I, et al. Epidemiological study of paratuberculosis in wild rabbits in Scotland. J Clin Microbiol. 1999;37:1746–51.PubMedCentralPubMed
17.
Beard PM, Daniels MJ, Henderson D, Pirie A, Rudge K, Buxton D, et al. Paratuberculosis infection of nonruminant wildlife in Scotland. J Clin Microbiol. 2001;39:1517–21.CrossRefPubMedCentralPubMed
18.
Sohal JS, Singh SV, Tyagi P, Subhodh S, Singh PK, Singh AV, et al. Immunology of mycobacterial infections: with special reference to Mycobacterium avium subspecies paratuberculosis. Immunobiology. 2008;213:585–98.CrossRefPubMed
19.
Coussens PM. Mycobacterium paratuberculosis and the bovine immune system. Anim Health Res Rev. 2001;2:141–62.PubMed
20.
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn’s disease. J Clin Microbiol. 1986;24:357–63.PubMedCentralPubMed
21.
Whittington RJ, Marshall DJ, Nicholls PJ, Marsh IB, Reddacliff LA. Survival and dormancy of Mycobacterium avium subsp. paratuberculosis in the environment. Appl Environ Microbiol. 2004;70:2989–3004.CrossRefPubMedCentralPubMed
22.
Grant IR, Ball HJ, Rowe MT. Incidence of Mycobacterium paratuberculosis in bulk raw and commercially pasteurized cows’ milk from approved dairy processing establishments in the United Kingdom. Appl Env Microbiol. 2002;68:2428–35.CrossRef
23.
24.
Keswani J, Frank JF. Thermal inactivation of Mycobacterium paratuberculosis in milk. J Food Prot. 1998;61:974–8.PubMed
25.
Gao A, Mutharia L, Chen S, Rahn K, Odumeru J. Effect of pasteurization on survival of Mycobacterium paratuberculosis in milk. J Dairy Sci. 2002;85:3198–205.CrossRefPubMed
26.
Donaghy JA, Totton NL, Rowe MT. Persistence of Mycobacterium paratuberculosis during manufacture and ripening of cheddar cheese. Appl Environ Microbiol. 2004;70:4899–905.CrossRefPubMedCentralPubMed
27.
Whan LB, Grant IR, Ball HJ, Scott R, Rowe MT. Bactericidal effect of chlorine on Mycobacterium paratuberculosis in drinking water. Lett Appl Microbiol. 2001;33:227–31.CrossRefPubMed
28.
Economou M, Pappas G. New global map of Crohn’s disease: Genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis. 2008;14:709–20.CrossRefPubMed
29.
30.
Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B-S, Bizzaro N, et al. Infectious serologies and autoantibodies in inflammatory bowel disease. Ann N Y Acad Sci. 2009;1173:640–8.CrossRefPubMed
31.
Marks DJB, Harbord MWN, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet. 2006;367:668–78.CrossRefPubMed
32.
33.
34.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–6.CrossRefPubMed
35.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.CrossRefPubMed
36.
Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2 implications for Crohn's disease. J Biol Chem. 2003;278:5509–12.CrossRefPubMed
37.
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869–72.CrossRefPubMed
38.
Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJP, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867–74.CrossRefPubMed
39.
Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–4.CrossRefPubMed
40.
Maeda S, Hsu L-C, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 mutation in Crohn’s disease potentiates NF-kappa B activity and IL-1 beta processing. Science. 2005;307:734–8.CrossRefPubMed
41.
42.
Parkes M, Barrett JC, Prescott N, Tremelling M, Anderson CA, Fisher SA, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn disease susceptibility. Nat Genet. 2007;39:830–2.CrossRefPubMedCentralPubMed
43.
Naser SA, Hulten K, Shafran I, Graham DY, El-Zaatari FA. Specific seroreactivity of Crohn’s disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol. 2000;77:497–504.CrossRefPubMed
44.
Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn’s disease and ulcerative colitis. J Clin Microbiol. 2004;42:1129–35.CrossRefPubMedCentralPubMed
45.
Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, et al. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol. 2000;38:4373–81.PubMedCentralPubMed
46.
Scharl M, Rogler G. Microbial sensing by the intestinal epithelium in the pathogenesis of inflammatory bowel disease. Int J Inflamm. 2010;2010:e671258.CrossRef
47.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627–40.CrossRefPubMed
48.
Ferwerda G, Kullberg BJ, de Jong DJ, Girardin SE, Langenberg DML, van Crevel R, et al. Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J Leukoc Biol. 2007;82:1011–8.CrossRefPubMed
49.
Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease correlates with enhanced TNF-alpha secretion. Dig Liver Dis. 2007;39:445–51.CrossRefPubMed
50.
Nakase H, Tamaki H, Matsuura M, Chiba T, Okazaki K. Involvement of Mycobacterium avium subspecies paratuberculosis in TNF-alpha production from macrophage: possible link between MAP and immune response in Crohn’s disease. Inflamm Bowel Dis. 2011;17:E140–2.CrossRefPubMed
51.
Bach H, Rosenfeld G, Bressler B. Treatment of Crohn’s disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins. J Crohns Colitis. 2012;6:628–9.CrossRefPubMed
52.
Dotan I, Allez M, Nakazawa A, Brimnes J, Schulder-Katz M, Mayer L. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-γ. Am J Physiol - Gastrointest Liver Physiol. 2007;292:G1630–40.CrossRefPubMed
53.
Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol - Gastrointest Liver Physiol. 2009;296:G135–46.CrossRefPubMedCentralPubMed
54.
Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJB, Sewell GW, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med. 2009;206:1883–97.CrossRefPubMedCentralPubMed
55.
Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90–7.CrossRefPubMed
56.
Golan L, Livneh-Kol A, Gonen E, Yagel S, Rosenshine I, Shpigel NY. Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation. J Infect Dis. 2009;199:350–4.CrossRefPubMed
57.
Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.CrossRefPubMed
58.
Jones PH, Farver TB, Beaman B, Çetinkaya B, Morgan KL. Crohn’s disease in people exposed to clinical cases of bovine paratuberculosis. Epidemiol Infect. 2006;134:49–56.CrossRefPubMedCentralPubMed
59.
60.
Sandberg M, Nygard K, Meldal H, Valle PS, Kruse H, Skjerve E. Incidence trend and risk factors for campylobacter infections in humans in Norway. BMC Public Health. 2006;6:179.CrossRefPubMedCentralPubMed
61.
Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of Escherichia coli O157:H7 Outbreaks, United States, 1982-2002. Emerg Infect Dis. 2005;11:603–9.CrossRefPubMedCentralPubMed
62.
Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn’s disease. J Clin Microbiol. 1984;20:966–71.PubMedCentralPubMed
63.
Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn’s disease patients. Am J Gastroenterol. 2000;95:1094–5.CrossRefPubMed
64.
Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. Lancet. 2004;364:1039–44.CrossRefPubMed
65.
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, et al. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn’s disease. Gut. 2005;54:944–9.CrossRefPubMedCentralPubMed
66.
Rowbotham DS, Mapstone NP, Trejdosiewicz LK, Howdle PD, Quirke P. Mycobacterium paratuberculosis DNA not detected in Crohn’s disease tissue by fluorescent polymerase chain reaction. Gut. 1995;37:660–7.CrossRefPubMedCentralPubMed
67.
Clarkston WK, Presti ME, Petersen PF, Zachary PE, Fan WX, Leonardi CL, et al. Role of Mycobacterium paratuberculosis in Crohn’s disease: a prospective, controlled study using polymerase chain reaction. Dis Colon Rectum. 1998;41:195–9.CrossRefPubMed
68.
69.
Bull TJ, Hermon-Taylor J, Pavlik I, El-Zaatari F, Tizard M. Characterization of IS900 loci in Mycobacterium avium subsp. paratuberculosis and development of multiplex PCR typing. Microbiology. 2000;146:2185–97.PubMed
70.
Bernstein CN, Nayar G, Hamel A, Blanchard JF. Study of Animal-borne infections in the mucosas of patients with inflammatory bowel disease and population-based controls. J Clin Microbiol. 2003;41:4986–90.CrossRefPubMedCentralPubMed
71.
Tasara T, Stephan R. Development of an F57 sequence-based real-time PCR assay for detection of Mycobacterium avium subsp. paratuberculosis in milk. Appl Environ Microbiol. 2005;71:5957–68.CrossRefPubMedCentralPubMed
72.
Van Schaik G, Schukken YH, Crainiceanu C, Muskens J, VanLeeuwen JA. Prevalence estimates for paratuberculosis adjusted for test variability using Bayesian analysis. Prev Vet Med. 2003;60:281–95.CrossRefPubMed
73.
Wu C, Livesey M, Schmoller SK, Manning EJB, Steinberg H, Davis WC, et al. Invasion and persistence of Mycobacterium avium subsp. paratuberculosis during early stages of Johne’s disease in calves. Infect Immun. 2007;75:2110–9.CrossRefPubMedCentralPubMed
74.
Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol. 2000;164:2016–20.CrossRefPubMed
75.
Stanley SA, Raghavan S, Hwang WW, Cox JS. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A. 2003;100:13001–6.CrossRefPubMedCentralPubMed
76.
Bach H, Papavinasasundaram KG, Wong D, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. Cell Host Microbe. 2008;3:316–22.CrossRefPubMed
77.
Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H + -ATPase to inhibit phagosome acidification. Proc Natl Acad Sci U S A. 2011;108:19371–6.CrossRefPubMedCentralPubMed
78.
Momotani E, Whipple DL, Thiermann AB, Cheville NF. Role of M Cells and Macrophages in the entrance of Mycobacterium paratuberculosis into omdes of leal Peyer’s patches in calves. Vet Pathol Online. 1988;25:131–7.CrossRef
79.
Pott J, Basler T, Duerr CU, Rohde M, Goethe R, Hornef MW. Internalization-dependent recognition of Mycobacterium avium ssp. paratuberculosis by intestinal epithelial cells. Cell Microbiol. 2009;11:1802–15.CrossRefPubMed
80.
Bach H, Ko HH, Raizman EA, Attarian R, Cho B, Biet F, et al. Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn’s disease patients. Scand J Gastroenterol. 2011;46:30–9.CrossRefPubMed
81.
Hamilton HL, Follett DM, Siegfried LM, Czuprynski CJ. Intestinal multiplication of Mycobacterium paratuberculosis in athymic nude gnotobiotic mice. Infect Immun. 1989;57:225–30.PubMedCentralPubMed
82.
Schorey JS, Holsti MA, Ratliff TL, Allen PM, Brown EJ. Characterization of the fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding motif conserved among mycobacteria. Mol Microbiol. 1996;21:321–9.CrossRefPubMed
83.
Middleton AM, Chadwick MV, Nicholson AG, Dewar A, Groger RK, Brown EJ, et al. The role of Mycobacterium avium complex fibronectin attachment protein in adherence to the human respiratory mucosa. Mol Microbiol. 2000;38:381–91.CrossRefPubMed
84.
Secott TE, Lin TL, Wu CC. Fibronectin attachment protein homologue mediates fibronectin binding by Mycobacterium avium subsp. paratuberculosis. Infect Immun. 2001;69:2075–82.CrossRefPubMedCentralPubMed
85.
Kuehnel MP, Goethe R, Habermann A, Mueller E, Rohde M, Griffiths G, et al. Characterization of the intracellular survival of Mycobacterium avium ssp. paratuberculosis: phagosomal pH and fusogenicity in J774 macrophages compared with other mycobacteria. Cell Microbiol. 2001;3:551–66.CrossRefPubMed
86.
Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263:678–81.CrossRefPubMed
87.
Bach H, Sun J, Hmama Z, Av-Gay Y. Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection. Infect Immun. 2006;74:6540–6.CrossRefPubMedCentralPubMed
88.
Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, Huygen K, et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science. 2004;304:1800–4.CrossRefPubMed
89.
Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. PLoS One. 2007;2:e161.CrossRefPubMedCentralPubMed
90.
Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother. 2008;52:418–26.CrossRefPubMedCentralPubMed
91.
Greenstein RJ, Su L, Juste RA, Brown ST. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS One. 2008;3:e2496.CrossRefPubMedCentralPubMed
92.
Greenstein RJ, Su L, Brown ST. On the effect of thalidomide on Mycobacterium avium subspecies paratuberculosis in culture. Int J Infect Dis. 2009;13:e254–63.CrossRefPubMed
93.
Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year-outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother. 1997;39:393–400.CrossRefPubMed
94.
Shafran I, Kugler L, El-Zaatari F. a. K, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig Liver Dis. 2002;34:22–8.CrossRefPubMed
95.
Xia A, Stempak JM, Grist J, Bressler B, Silverberg MS, Bach H. Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins. Scand J Gastroenterol. 2014;49:157–63.CrossRefPubMed
96.
Larsen AB, Miller JM. Effect of dexamethasone on Mycobacterium paratuberculosis infection in hamsters. Am J Vet Res. 1978;39:1866–7.PubMed
97.
Li L, Bannantine JP, Zhang Q, Amonsin A, May BJ, Alt D, et al. The complete genome sequence of Mycobacterium avium subspecies paratuberculosis. Proc Natl Acad Sci U S A. 2005;102:12344–9.CrossRefPubMedCentralPubMed
98.
Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, Anderton MC, et al. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci U S A. 2007;104:1947–52.CrossRefPubMedCentralPubMed
Metadata
Title
What Role Does Mycobacterium avium subsp. paratuberculosis Play in Crohn’s Disease?
Author
Horacio Bach
Publication date
01-02-2015
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 2/2015
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-015-0463-z

Other articles of this Issue 2/2015

Current Infectious Disease Reports 2/2015 Go to the issue

Skin, Soft Tissue, Bone and Joint Infectious Diseases (N Safdar, Section Editor)

Cutaneous Manifestations of Viral Hepatitis

Central Nervous System Infections (J Lyons, Section Editor)

Update on Neurological Manifestations of HTLV-1 Infection

Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Water, Sanitation, and Hygiene at the World’s Largest Mass Gathering

Respiratory Infections (F Arnold, Section Editor)

Using Standardized Care Bundles in the Emergency Department to Decrease Mortality in Patients Presenting with Community-Acquired Pneumonia (CAP) and Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

Role of Novel Retroviruses in Chronic Liver Disease: Assessing the Link of Human Betaretrovirus with Primary Biliary Cirrhosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits